MCL1 and cancer: While direct inhibition of MCL1 has been the desired endpoint of drug development programs, indirect inhibition of MCL1 via NOXA induction may also provide an attractive therapy as it has been shown to sensitize various cancer cells to other BCL2 inhibitors13,14.